Pharmacology and Drug Classification

Brand name (proprietary name) is the company's trademarked name for a drug (e.g., Lipitor). Generic name (nonproprietary name) is the official chemical name (e.g., atorvastatin). A brand-name drug is patented for 20 years; during that time, only the originating company can make it, and price is high ($5–10+ per tablet). When the patent expires, other manufacturers can produce the generic version, and price drops to $0.10–1 per tablet. Brand and generic are chemically identical (same active ingredient, dose, route) and equally effective; the difference is cost and sometimes appearance (shape, color, inert ingredients like fillers). Pharmacist recommendation: choose generic unless the patient cannot tolerate the filler (rare allergy) or has previous therapeutic failure with a generic version. Generic saves the patient and insurance money. Brand-name drugs have brand loyalty marketing and sometimes better tablet size (smaller/easier to swallow), but this rarely justifies the price premium. Insurance often mandates generic unless a prior authorization for brand-only is approved. Answer: recommend generic 95% of the time.

Active ingredient is the chemical that causes the therapeutic effect (e.g., atorvastatin in a statin tablet lowers cholesterol). Inactive ingredients are binders, fillers, colorants, and flavoring agents that give the tablet its shape, size, taste, and shelf life but do not treat the disease. Examples: lactose (filler), talc (lubricant), FD&C Yellow #5 (dye), cellulose (binder). Why do they matter? (1) Allergies: a patient allergic to yellow dye cannot take any tablet with FD&C Yellow #5, even if the active drug is fine. (2) Intolerances: lactose intolerance means the patient cannot take lactose-filled tablets; a lactose-free formulation is needed. (3) Efficacy: some fillers slow drug release (e.g., a tablet with a lot of talc absorbs slowly; a formulation with less talc absorbs faster), affecting how quickly the drug works. (4) Stability: preservatives and packaging protect the active drug from degradation. Compounding or pharmaceutical companies can create custom tablets with different inactive ingredients to accommodate patient allergies or sensitivities. For example, an allergist might compound allergy medication without dye for a sensitive child. Always ask patients about intolerances when dispensing a new drug.

Half-life is the time it takes for the body to eliminate half of the drug dose. Example: amoxicillin has a half-life of 1 hour; if you take 500 mg, after 1 hour 250 mg remains, after 2 hours 125 mg remains, and so on. Half-life affects dosing frequency: (1) Short half-life (minutes to hours, e.g., penicillin, warfarin): must be dosed frequently (every 4–6 hours or daily) to maintain therapeutic levels. (2) Long half-life (hours to days, e.g., digoxin, some statins): dosed once daily or less frequently because the drug accumulates. (3) Very long half-life (days to weeks, e.g., methotrexate, some antibiotics like azithromycin): dosed weekly or spaced out over days. Clinical significance: (1) Dosing convenience: once-daily drugs improve adherence over four-times-daily. (2) Missed dose impact: missing one dose of a long-acting drug is less critical; missing one dose of a short-acting drug means a drop in levels and loss of effect. (3) Accumulation: with repeated dosing, the body's drug level rises until it reaches a 'steady state' (usually 5× the half-life). If a drug accumulates, watch for toxicity (especially in elderly with kidney disease). (4) Drug interactions: a new drug that inhibits metabolism of an existing drug with a long half-life can cause slow accumulation and delayed toxicity (dangerous). Understanding half-life helps predict drug behavior and counsel patients on missed doses.

Therapeutic window (or therapeutic range) is the blood concentration of a drug where it is effective but not toxic. Example: digoxin (a heart drug) has a therapeutic range of 0.8–2 ng/mL. Below 0.8 = ineffective (patient's heart rhythm worsens). Above 2 = toxic (arrhythmias, nausea, hyperkalemia, death). Some drugs have a wide therapeutic window (e.g., most antibiotics; overdosing by a factor of 2–3 is usually safe). Other drugs have a narrow therapeutic window (e.g., warfarin, digoxin, theophylline, lithium): a 20% change in blood level can be the difference between therapeutic and toxic. Narrow-window drugs require therapeutic drug monitoring (TDM): regular blood tests to measure the drug level and adjust doses. Sub-therapeutic levels: patient symptoms persist or worsen; disease progresses unchecked (e.g., seizures not controlled if phenytoin level is low). Toxic levels: side effects develop (nausea, tremor, organ damage); the drug becomes harmful. Managing narrow-window drugs: (1) baseline TDM lab to establish the patient's level, (2) repeat labs after dose changes or if symptoms develop, (3) educate the patient on consistency (take at the same time daily, consistent diet if applicable). Narrow-window drugs account for a large fraction of medication-related hospital admissions; understanding this concept is critical for safety.

Bioavailability is the percentage of an administered drug dose that reaches systemic circulation (the bloodstream). IV (intravenous) has 100% bioavailability: the drug is injected directly into a vein and immediately circulates everywhere. IM (intramuscular) has ~80–90% bioavailability: the drug is injected into muscle, slowly absorbed through the muscle capillaries into the bloodstream; there is minimal loss but some delay. Oral (by mouth) has 20–80% bioavailability depending on the drug: the drug is swallowed, absorbed through the GI tract, then passes through the liver (first-pass metabolism) before entering systemic circulation. If the liver breaks down >50% of the drug before it reaches the bloodstream, oral bioavailability is low and a higher oral dose is needed compared to IV. Example: nitroglycerin (heart medication) has low oral bioavailability (~10%) due to first-pass metabolism; a sublingual (under-the-tongue) formulation bypasses the GI tract and liver, achieving much higher bioavailability and faster action. Topical (cream) and transdermal (patch) have variable bioavailability depending on skin penetration; some drugs are designed specifically for patches because oral administration would require impractically large doses. Clinical impact: (1) Dose differences: IV doses are often much lower than oral doses of the same drug (e.g., metoprolol: 50 mg oral daily vs. 5 mg IV). (2) Onset time: IV is fastest (minutes), oral is slower (30 minutes to hours). (3) Food interactions: some oral drugs are absorbed faster with food; others require empty stomach. Understanding bioavailability explains why routes matter and why switching routes requires dose adjustment.

First-pass metabolism (or first-pass effect) occurs when an oral drug is absorbed through the GI tract and travels via the portal vein to the liver before entering the general circulation. The liver's enzymes (CYP450, others) metabolize (break down) a portion of the drug; the remaining amount enters systemic circulation. Drugs heavily metabolized by the liver during first pass have low oral bioavailability and require high oral doses (or are not practical to give orally at all). Examples of high first-pass drugs: (1) Nitroglycerin: only 10% oral bioavailability; must be given sublingually or transdermal. (2) Propranolol: oral bioavailability 20–30%; IV dose is much lower. (3) Lidocaine (local anesthetic): oral bioavailability ~35%; ineffective as an oral analgesic, only used IV or topical. (4) Some opioids (morphine): oral bioavailability ~20–30%; oral doses are 3–5× IV doses. Implications: (1) Route selection: if a drug has high first-pass metabolism, oral is impractical; choose IV, IM, transdermal, sublingual, or rectal. (2) Drug interactions: a new CYP450 inhibitor can reduce first-pass metabolism, raising the oral drug level unpredictably. Example: clarithromycin (antibiotic, CYP3A4 inhibitor) increases propranolol levels by blocking first-pass metabolism. (3) Liver disease: patients with cirrhosis or portal hypertension have reduced first-pass metabolism; standard oral doses become toxic. Screening for first-pass metabolism is important when prescribing oral drugs to patients with liver disease or when adding drugs that inhibit the metabolizing enzyme.

Side effect is a mild, expected pharmacologic consequence of a drug that usually improves over time (e.g., dry mouth from antihistamines, drowsiness from antidepressants on the first few doses). Patients often tolerate side effects as the price of benefit. Adverse reaction (or adverse event, AE) is a harmful, unintended effect that can be serious and may require stopping the drug or changing doses (e.g., anaphylaxis from penicillin, Stevens-Johnson syndrome from antibiotics, liver damage from acetaminophen overdose). Counseling approach: (1) Warn about expected side effects ('This may make you drowsy for a few days; it usually improves'). (2) Offer mitigation ('Take it at night if it makes you tired'). (3) Emphasize duration ('Most people feel better after a week'). (4) Ask for feedback: 'If the side effect doesn't improve or worsens, call me.' (5) Describe serious adverse reactions ('If you get a severe rash, stop the drug and go to the ER'). (6) Stress benefit vs. risk: 'This drug prevents your heart attack even though it might cause heartburn; heartburn is better than a heart attack.' The ability to distinguish side effects (tolerable, temporary) from adverse reactions (serious, stop the drug) protects patients from discontinuing good medications due to minor side effects, while also catching rare serious reactions early.

High-alert drugs are medications with a narrow therapeutic window or high risk of serious harm if dosed wrong, given to the wrong patient, or misdispensed. Examples: insulin, warfarin, digoxin, opioids, chemotherapy, potassium chloride, heparin, and liothyronine (thyroid). Special precautions: (1) Double-check: prescriber verifies the order, pharmacist verifies the patient and dose, and nurse verifies before administration. Three independent verification points. (2) Use taller-man lettering on labels (e.g., InSULin vs. insullin) to catch look-alike mistakes. (3) Standardize: use pre-filled syringes or single-dose vials instead of multi-dose vials (reduces chance of wrong patient grabbing a vial meant for someone else). (4) Barcode scanning: scan the patient, the medication, and the nurse before administration. (5) Limit access: keep high-alert drugs in locked cabinets or automated dispensers. (6) Separate storage: keep similar-sounding drugs (like lisinopril vs. linezolid) far apart on the shelf. (7) Computer alerts: EHR flags high-alert drugs and requires extra confirmation before order entry. (8) Dosing limits: EHR rejects doses outside a predefined safe range (e.g., insulin >100 units per dose requires manual override). (9) Education: frequent training on high-alert drugs, case reviews of near-misses, and a culture of 'pause and verify' rather than rushing. Hospitals and pharmacies that systematize high-alert drug management see dramatic reductions in errors and harm.